戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  support for inclusion of this molecule in a meningococcal vaccine.
2 ingitidis serogroups included in the current meningococcal vaccine.
3 nactivated influenza vaccine or quadrivalent meningococcal vaccine.
4 lopment not only for gonorrhoea but also for meningococcal vaccines.
5 rvations support the incorporation of Opa in meningococcal vaccines.
6 ructure that may affect the effectiveness of meningococcal vaccines.
7 al, Haemophilus influenzae type b (Hib), and meningococcal vaccines.
8 ome outer membrane protein-based serogroup B meningococcal vaccines.
9 -vaccine era, use of a polyvalent conjugated meningococcal vaccine, and influenza vaccination during
10 s to factor H (fH)-binding protein (fHBP), a meningococcal vaccine antigen, activate classical comple
11                                          The meningococcal vaccine antigen, factor H (FH)-binding pro
12 tibody production in mice and is a candidate meningococcal vaccine antigen.
13 eful characteristic for an effective group B meningococcal vaccine antigen.
14                                Other group B meningococcal vaccines are in development.
15                                          New meningococcal vaccines are undergoing clinical trials, a
16                            Patients received meningococcal vaccine at a screening visit and 2 weeks l
17                                          The meningococcal vaccine candidate factor H binding protein
18                                          The meningococcal vaccine candidate factor H-binding protein
19 Genome-derived neisserial Ag (GNA) 1870 is a meningococcal vaccine candidate that can be subdivided i
20   Factor H-binding protein (fHbp) is a novel meningococcal vaccine candidate that elicits serum antib
21 embrane protein previously investigated as a meningococcal vaccine candidate.
22 rrently under evaluation as a broad-spectrum meningococcal vaccine candidate.
23 proteins that have been considered potential meningococcal vaccine candidates.
24 te that molecular mimetics have potential as meningococcal vaccine candidates.
25                                    The older meningococcal vaccine, composed of capsular polysacchari
26  tetravalent (serogroups A, C, Y, and W-135) meningococcal vaccine conjugated to diphtheria toxoid at
27                                              Meningococcal vaccines containing factor H binding prote
28 ived 3 doses of outer-membrane protein (OMP) meningococcal vaccine developed in either Cuba or Norway
29 creased in recent years, but the efficacy of meningococcal vaccine during mass vaccination campaigns
30 and cerebrospinal fluid (CSF) samples from a meningococcal vaccine field trial performed in Iquique,
31                      Use of the quadrivalent meningococcal vaccine for control of outbreaks has incre
32 a demonstrate the feasibility of preparing a meningococcal vaccine from a single recombinant protein
33 cine group than in those in the quadrivalent meningococcal vaccine group (n=60 vs n=37; p=0.02).
34 eported in 60 (3%) women in the quadrivalent meningococcal vaccine group and 61 (3%) women in the tri
35 ere first episodes (n=77 in the quadrivalent meningococcal vaccine group vs n=52 in the trivalent ina
36 93 (88%) of 2041 infants in the quadrivalent meningococcal vaccine group were followed up until age 6
37 round the world, and a hexavalent PorA-based meningococcal vaccine has recently been developed in The
38  A significant problem in efficacy trials of meningococcal vaccines has been accurate identification
39                                New conjugate meningococcal vaccines have successfully reduced endemic
40 e candidates in the search for comprehensive meningococcal vaccines; however, the formulation of OMP
41 p vaccine), meningococcal disease (conjugate meningococcal vaccine), human papillomavirus (for female
42 re potentially preventable with the licensed meningococcal vaccine in 82.8% of 15 through 24 year old
43 llenge will be effective introduction of new meningococcal vaccines into developing countries, especi
44                       The presently licensed meningococcal vaccine is a tetravalent capsular polysacc
45                           Herd protection by meningococcal vaccines is conferred by population-level
46                Assessment of new serogroup B meningococcal vaccines is hampered by a scarcity of data
47 opose that outer membrane vesicle-containing meningococcal vaccines may be more efficacious if purged
48 -OMVs as adjuvants or as portions of group B meningococcal vaccines may help improve survival and out
49 in SLSJ, using the 4-component protein-based meningococcal vaccine (MenB-4C).
50 ng protein (fHbp; a key component of group B meningococcal vaccines) molecule.
51 d influenza vaccine (n=2108) or quadrivalent meningococcal vaccine (n=2085).
52 ve either an influenza vaccine or a control (meningococcal vaccine, pneumococcal vaccine, or placebo)
53 families and cost-effectiveness analyses for meningococcal vaccine programs.
54                                  The group A meningococcal vaccine (PsA-TT) clinical development plan
55   During the first introduction of a group A meningococcal vaccine (PsA-TT) in 2010-2011 and its roll
56                   The rollout of the group A meningococcal vaccine, PsA-TT, in Africa's meningitis be
57 hat for serogroups prevented by quadrivalent meningococcal vaccines, public health response to outbre
58 f tetanus/diphtheria/acellular pertussis and meningococcal vaccines, respectively, was delayed by 1 w
59                               In 2005, a new meningococcal vaccine, tetravalent meningococcal conjuga
60  was more common in women given quadrivalent meningococcal vaccine than in those given trivalent inac
61 ongoing to develop a serogroup B vaccine and meningococcal vaccines that are immunogenic in infants a
62                                              Meningococcal vaccines that target both NspA and FHbp ar
63                          A conjugate group A meningococcal vaccine to prevent epidemics of meningitis
64 d diagnostic of disease in future testing of meningococcal vaccines to improve efficacy analyses.
65                      A 'tailor-made' group B meningococcal vaccine was successfully used to control a
66      Children and adult recipients of either meningococcal vaccine were more likely than controls to
67 vels elicited by two efficacious serogroup B meningococcal vaccines were measured in a controlled tri
68 i-TT), Vi-polysaccharide (Vi-PS), or control meningococcal vaccine with a computer-generated randomis
69 se data suggest that neither serogroup B OMP meningococcal vaccine would confer protection during a h

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。